Adare Pharma Solutions, a global technology-driven CDMO company specialising in oral dosage forms, announced a collaboration with Laxxon Medical, a pharmaceutical technology company developing a new generation of advanced pharmaceuticals, to provide cGMP 3D printing capabilities to the pharmaceutical market from Adare’s site in Pessano, Italy.
This partnership is based on the Screen-Printed Innovative Drug (SPID) technology licensed from Exentis Group, which enables the production of complex drugs with advanced internal structures and customised release profiles.
Tom Sellig, CEO of Adare Pharma Solutions said, “Our Pessano facility provides comprehensive CDMO solutions to customers in Europe, the United States, and Asia. Adare’s collaboration with Laxxon expands our ability to provide incredible dose flexibility options such as taste masking, solubility enhancement, shape modifications for ease of swallowing, and multiple APIs.”
The use of this 3D printing technology makes it possible to print tablets with multiple active ingredients and customised release. This offers improved bioavailability and optimised pharmacokinetic properties. Of particular note is the ability to create multi-compartmentalised tablets that can vary from a few micrometres to several centimetres in diameter. This technology also allows for seamless scaling from laboratory operations to mass production without the need for changes in the manufacturing process.
Adare has already installed the necessary 3D printing systems and a new mixer in its Pessano facility. The systems are expected to be fully operational by the end of 2024. Laxxon Medical sees the partnership as a decisive step in the further development of disruptive drug technologies.
“Laxxon’s partnership with Adare represents a significant step forward in actualizing our mission to drive disruptive global drug delivery and manufacturing solutions,”
Helmut Kerschbaumer, CEO of Laxxon Medical, said. “This is an essential collaboration for Laxxon; Adare, with their CDMO expertise and state-of-the-art cGMP facilities, will enable us to produce clinical samples for our partners as well as our own internal pipeline.”
The collaboration aims to make pharmaceutical production more efficient and customisable through the 3D printing of drugs.
Subscribe to our Newsletter
3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
